Background Obesity is associated with heart failure with preserved ejection fraction (HFpEF). Weight loss can improve exercise capacity in HFpEF. However, previously reported methods of weight loss are impractical for widespread clinical implementation. We tested the hypothesis that an intensive lifestyle modification program would lead to relevant weight loss and improvement in functional status in patients with HFpEF and obesity. Methods and Results Patients with ejection fraction >45%, at least 1 objective criteria for HFpEF, and body mass index ≥30 kg/m 2 were offered enrollment in an established 15‐week weight management program that included weekly visits for counseling, weight checks, and provision of meal replacements. At baseline, 15 weeks, and 26 weeks, Minnesota Living With Heart Failure score, 6‐minute walk distance, echocardiography, and laboratory variables were assessed. A total of 41 patients completed the study (mean body mass index, 40.8 kg/m 2 ), 74% of whom lost >5% of their baseline body weight following the 15‐week program. At 15 weeks, mean 6‐minute walk distance increased from 223 to 281 m ( P =0.001) and then decreased to 267 m at 26 weeks. Minnesota Living With Heart Failure score improved from 59.9 to 37.3 at 15 weeks ( P <0.001) and 37.06 at 26 weeks. Changes in weight correlated with change in Minnesota Living With Heart Failure score ( r =0.452; P =0.000) and 6‐minute walk distance ( r =−0.388; P <0.001). Conclusions In a diverse population of patients with obesity and HFpEF, clinically relevant weight loss can be achieved with a pragmatic 15‐week program. This is associated with significant improvements in quality of life and exercise capacity. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02911337.

Right ventricular outflow tract (RVOT) and pulmonary valve dysfunction are commonly seen in pediatric patients, particularly those with Tetralogy of Fallot. 1 Most of these patients undergo surgical repair with the expectation that they may require surgical re-intervention to replace a regurgitant pulmonary valve or to relieve RVOT stenosis. 2 The first transcatheter pulmonary valve implantation was performed by Bonhoeffer et al. 3 in early 2000 with a right ventricle-to-pulmonary artery (RV-PA) conduit.

No abstract

Key Points The NeoVas sirolimus‐eluting bioresorbable stent is safe and efficacious for treating de novo coronary artery disease. Lesion and patient‐specific characteristics may play a role in the long‐term safety profile of bioresorbable stents. The role of bioresorbable scaffolds in complex coronary lesions needs to be further elucidated.

Tricuspid regurgitation (TR) is a common type of age-related valve disease associated with a poor prognosis, even in patients who receive optimal medical therapy. In patients who undergo isolated tricuspid valve (TV) surgery, the operative mortality rate is 10%. 1 Thus, additional approaches for managing TR are needed. The 2021 European Society of Cardiology/European Association for Cardio-Thoracic Surgery Guidelines for managing valvular heart disease suggested a potential role for the use of transcatheter TV intervention in patients with TR who are at high surgical risk. 2